About 118 results.

LENVATINIB MESYLATE

<span class='lighter'>LENVATINIB</span> <span class='lighter'>MESYLATE</span>

CCD:CCD04334152

CAS:857890-39-2

MDL:MFCD18633219

MF / MW:C21 H19 Cl N4 O4 . C H4 O3 S / 522.964

Synonyms:乐伐替尼;LENVATINIB MESYLATE;4-(3-CHLORO-4-[(CYCLOPROPYLCARBAMOYL)AMINO]PHENOX)-7-METHOXYQUINOLINE-6-CARBOXAMIDE, METHANESULFONIC ACID

http://www.chemcd.com/prodetailCCD04334152.html

卫材新型抗癌药lenvatinib一线治疗晚期肾细胞癌(RCC)进入III期临床开发

卫材新型抗癌药<span class='lighter'>lenvatinib</span>一线治疗晚期肾细胞癌(RCC)进入III期临床开发
2016-10-08 lenvatinib是一种新型口服多受体酪氨酸激酶(RTK)抑制剂,目前已在美日欧3大市场上市,用于难治性甲状腺癌的治疗;同时已获美欧批准治疗晚期肾细胞癌。
http://www.chemcd.com/news/32655.html

卫材向欧盟提交新型抗癌药lenvatinib肾细胞癌适应症申请

卫材向欧盟提交新型抗癌药<span class='lighter'>lenvatinib</span>肾细胞癌适应症申请
2016-01-15 lenvatinib是一种口服多受体酪氨酸激酶(RTK)抑制剂,目前已在美日欧3大市场上市,用于难治性甲状腺癌的治疗。
http://www.chemcd.com/news/23075.html

U.S. FDA Grants Priority Review Status to NDA for Anticancer Agent Lenvatinib

2014-10-17 Eisai Co., Ltd.announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) submitted by its U.S. subsidiary Eisai Inc. for its novel in-house developed anticancer agent lenvatinib mesylate (lenvatinib) as a treatment for progressive radioiodine-refractory differentiated thyroid cancer and granted the NDA Priority Review status.

http://www.chemcd.com/news/5951.html

欧美加速审批—卫材甲状腺癌新药lenvatinib收获在望

2014-10-17 日欧美3大市场均授予lenvatinib孤儿药地位,欧美还授予加速审查和优先审查资格,最快预计在2015年4月获批。

http://www.chemcd.com/news/5921.html

Lenvatinib

<span class='lighter'>Lenvatinib</span>
2016-12-10 25G Stock;417716-92-8
http://www.chemcd.com/info/sell/88442.html

卫材向美国和欧盟提交新型靶向抗癌药lenvatinib一线治疗肝细胞癌(HCC)新适应症申请

卫材向美国和欧盟提交新型靶向抗癌药<span class='lighter'>lenvatinib</span>一线治疗肝细胞癌(HCC)新适应症申请
2017-07-26  2017年7月26日讯 /生物谷BIOON/ --日本药企卫材(Eisai)近日宣布,已向美国食品和药物管理局(FDA)和欧洲药品管理局(EMA)提交了其自主研发的新型靶向抗...
http://www.chemcd.com/news/39444.html